MERZ-AESTHETICS
Merz Aesthetics is presenting at the 2024 International Master Course on Aging Science (IMCAS) World Congress a total of 5 abstracts highlighting the field of regenerative aesthetics and how its product portfolio is contributing. This year’s IMCAS is the 25th edition of the largest scientific aesthetics congress worldwide beginning Thursday, February 1st to Saturday, February 3.
“Merz Aesthetics is looking forward to sharing these new findings, as they provide strong scientific evidence to support the evolving field of regenerative aesthetics,” said Terri Phillips, M.D., Chief Medical Affairs Officer, Merz Aesthetics. “We take pride in the innovation of our product portfolio and how it’s helping to shape the future of the aesthetics industry.”
“Our focus in this year’s Merz Aesthetics sponsored symposium at the IMCAS Congress is the future of regenerative biostimulation with Radiesse”, said Gonzalo Mibelli, President EMEA, Merz Aesthetics. “Together with a panel of renowned industry experts we discuss the topic of skin regeneration, share insights into techniques and personalized treatment approaches aligned with our Merz Aesthetics commitment on scientific exchange and innovation.”
Merz Aesthetics organized a program led by notable medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the event.
- Merz Aesthetics sponsored symposium “Mastering regenerative biostimulation” – Dr. Gabriela Casabona, Dr. Tatjana Pavicic, Dr. Jani van Loghem, Dr. Bianca Viscomi, Friday, February 2, 2024, 4:00 p.m. – 6:00 p.m. CEST
- Merz Aesthetics support of IMCAS Cadaver Workshop – Anatomist Dr. Nicholas Moellhoff and Aesthetic Specialist Dr. Jonathan Kadouch, Thursday, February 1, 2024, 2:30 p.m. – 3:30 p.m. CEST
- IMCAS Product Analysis Session “Biostimulators” – Dr. Alec McCarthy, Director Regenerative Aesthetics, Merz Aesthetics, Friday, February 2, 2024, 8:30 a.m. ‒ 10:00 a.m. CEST
- IMCAS Product Analysis Session “Toxins” – PH.D. Andy Curry, associate medical director, Merz Aesthetics, Saturday, February 3, 2024, 8:30 a.m. ‒ 10:00 a.m. CEST
- IMCAS Economic Tribune Roundtable – Bob Rhatigan, CEO Merz Aesthetics, Friday, February 2, 2024, 2:00 p.m. – 3:30 p.m. CEST
Booth Talks
- Treatment Options for Hand Rejuvenation - Dr. Elena Bagnenko, Thursday, February 1, 2024, 1:00p.m. – 1.30 p.m.
- Innovative Technique for Tear Trough Correction - Dr. Yahia Hashish, Thursday, February 1, 2024, 3:30p.m. – 4.00 p.m.
- What are THE Really Important Aspects when using CaHA as a Regenerative Biostimulator? - Dr. Gabriela Casabona, Friday, February 2, 10:00 a.m. – 10.30 a.m.
- Advancing Skin Radiance, Dr. Juan Martín Zárate González, Friday, February 2, 1:00 p.m. – 1.30 p.m.
- Combination of Treatments for Improving Skin Quality - Dr. Ana Diez Gandia, Saturday, February 3, 2024, 10:00 a.m. – 10.30 a.m.
E-Poster Presentations
Virtual posters will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts.
- A review of Radiesse as a regenerative aesthetic treatment. Presenting author: Dr. Shino Bay Aguilera. Co-Authors: Dr. Alec McCarthy, Dr. Saami Khalifian, Dr.Z. Paul Lorenc, Dr. Katherine Goldie, Dr. W. Gregory Chernoff
- The evolving field of regenerative aesthetics. Presenting author: Dr. Katherine Goldie
- Physical properties of diluted Radiesse. Presenting author: Dr. Vasanop Vachiramon. Co-authors: Dr. Chayanee Likitwattananurak, Dr. Nawara Sakpuwadol, Dr. Tanat Yongpisarn
- Attraction of fibroblasts by Micro-Focused Ultrasound (MFU-V). Presenting author: Dr. Kay Marquardt. Co-authors: Dr. F. Wegener, Dr. Nils Warfving, Dr. Christian Hartmann, Dr. Dr. Thomas Hengl
- Retrospective case series following patients treated with a combination of CPM-HA and CaHA fillers. Presenting author: Dr. Bianca Viscomi Co-authors: Dr. Yana Yutskovskaya, Dr. Heidi Waldorf, Dr. Ting Song Lim
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2024 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201288217/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom